CREST, a Cas13-Based, Rugged, Equitable, Scalable Testing (CREST) for SARS-CoV-2 Detection in Patient Samples.

Autor: Aralis Z; UC Santa Barbara, Santa Barbara, California., Rauch JN; University of Massachusetts Amherst, Amherst, Massachusetts., Audouard M; UC Santa Barbara, Santa Barbara, California., Valois E; UC Santa Barbara, Santa Barbara, California., Lach RS; UC Santa Barbara, Santa Barbara, California., Solley S; UC Santa Barbara, Santa Barbara, California., Baxter NJ; UC Santa Barbara, Santa Barbara, California., Kosik KS; UC Santa Barbara, Santa Barbara, California., Wilson MZ; UC Santa Barbara, Santa Barbara, California., Acosta-Alvear D; UC Santa Barbara, Santa Barbara, California., Arias C; UC Santa Barbara, Santa Barbara, California.
Jazyk: angličtina
Zdroj: Current protocols [Curr Protoc] 2022 Feb; Vol. 2 (2), pp. e385.
DOI: 10.1002/cpz1.385
Abstrakt: The COVID-19 pandemic has taken a devastating human toll worldwide. The development of impactful guidelines and measures for controlling the COVID-19 pandemic requires continuous and widespread testing of suspected cases and their contacts through accurate, accessible, and reliable methods for SARS-CoV-2 detection. Here we describe a CRISPR-Cas13-based method for the detection of SARS-CoV-2. The assay is called CREST (Cas13-based, rugged, equitable, scalable testing), and is specific, sensitive, and highly accessible. As such, CREST may provide a low-cost and dependable alternative for SARS-CoV-2 surveillance. © 2022 Wiley Periodicals LLC. Basic Protocol: Cas13-ased detection of SARS-CoV-2 genetic material using a real-time PCR detection system Alternate Protocol: Cas13-based detection of SARS-CoV-2 genetic material using a fluorescence viewer Support Protocol 1: LwaCas13a purification Support Protocol 2: In vitro transcription of synthetic targets.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: